GSK plc announced on April 8, 2026, that their drug Exdensur (depemokimab) has been approved in China for treating chronic rhinosinusitis with nasal polyps (CRSwNP), becoming the first ultra-long-acting biologic for this condition. The approval is based on trials showing significant improvements in patients' nasal polyp size and obstruction, addressing a critical need for effective treatment in this underserved patient population.